News | July 26, 2022
GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr
GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022
GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022
With this, the company can start selling Ibuprofen in the European markets.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
Manish led SeQuent since 2014 and played a major role in transforming the company
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
George Svokos joins Avet after serving as a strategic business advisor to numerous global healthcare companies
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
Subscribe To Our Newsletter & Stay Updated
